Allworth Financial LP Purchases Shares of 4,611 Cardinal Health, Inc. $CAH

Key Points

• Allworth Financial acquired 4,611 Cardinal Health shares worth approximately $1.1 million, while institutional ownership reached 87.17% after several other funds added or initiated positions.
• Cardinal Health reported quarterly EPS of $2.91, beating the $2.42 consensus estimate, with revenue up 5.8% year over year. Fiscal 2027 EPS guidance is $12.40–$12.60, and analysts maintain a “Moderate Buy” consensus with an average price target of $266.56.
• The company declared a quarterly dividend of $0.5158 per share, but sizable insider selling and concerns that a one-time tariff refund contributed to the earnings beat may temper investor enthusiasm.

Allworth Financial LP acquired a new stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 4,611 shares of the company's stock, valued at approximately $1,095,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new position in Cardinal Health in the 2nd quarter worth approximately $308,640,000. Kornitzer Capital Management Inc. KS boosted its position in Cardinal Health by 100.8% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 18,164 shares of the company's stock valued at $3,733,000 after buying an additional 9,120 shares during the last quarter. Abacus FCF Advisors LLC acquired a new stake in shares of Cardinal Health in the 4th quarter valued at $7,182,000. Byrne Financial Freedom LLC acquired a new stake in shares of Cardinal Health in the 4th quarter valued at $1,574,000. Finally, Belleair Asset Management LLC bought a new stake in shares of Cardinal Health during the fourth quarter worth $1,100,000. 87.17% of the stock is owned by institutional investors.

Cardinal Health Trading Up 0.4%

NYSE:CAH opened at $229.48 on Friday. Cardinal Health, Inc. has a 1-year low of $145.87 and a 1-year high of $258.30. The firm has a market capitalization of $53.37 billion, a price-to-earnings ratio of 31.74, a PEG ratio of 1.23 and a beta of 0.49. The business's 50-day moving average price is $232.02 and its two-hundred day moving average price is $217.86.

Cardinal Health (NYSE:CAH - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The company had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same period in the previous year, the company earned $2.08 EPS. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts predict that Cardinal Health, Inc. will post 12.54 earnings per share for the current year.

Cardinal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be issued a $0.5158 dividend. The ex-dividend date is Thursday, October 1st. This represents a $2.06 annualized dividend and a yield of 0.9%. Cardinal Health's dividend payout ratio (DPR) is 28.49%.

Insider Activity at Cardinal Health

In related news, CEO Deborah Weitzman sold 7,354 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total value of $1,731,499.30. Following the completion of the sale, the chief executive officer owned 77,901 shares in the company, valued at $18,341,790.45. This represents a 8.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jessica L. Mayer sold 29,436 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total value of $6,952,488.84. Following the sale, the insider directly owned 33,076 shares in the company, valued at $7,812,220.44. The trade was a 47.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 210,271 shares of company stock valued at $49,626,657. 0.12% of the stock is owned by corporate insiders.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Citigroup upped their target price on shares of Cardinal Health from $265.00 to $280.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. William Blair initiated coverage on shares of Cardinal Health in a research report on Tuesday, April 28th. They set an "outperform" rating for the company. UBS Group boosted their price target on shares of Cardinal Health from $274.00 to $280.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. TD Cowen increased their price objective on shares of Cardinal Health from $275.00 to $280.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Finally, Weiss Ratings cut shares of Cardinal Health from a "buy (b+)" rating to a "buy (b)" rating in a research note on Wednesday. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $266.56.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source